Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells

Failed T cell-based immunotherapies in the presence of genomic alterations in antigen presentations pathways may be overcome by NK cell-based immunotherapy. This approach may still be limited by the presence of immunosuppressive myeloid populations. Here, we demonstrate that NK cells (haNKs) enginee...

Full description

Bibliographic Details
Main Authors: Yvette Robbins, Sarah Greene, Jay Friedman, Paul E Clavijo, Carter Van Waes, Kellsye P Fabian, Michelle R Padget, Houssein Abdul Sater, John H Lee, Patrick Soon-Shiong, James Gulley, Jeffrey Schlom, James W Hodge, Clint T Allen
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2020-07-01
Series:eLife
Subjects:
NK cells
chimerica antigen receptor
PD-L1
syngeneic
myeloid
xenograft
Online Access:https://elifesciences.org/articles/54854

Internet

https://elifesciences.org/articles/54854

Similar Items